Scandion Oncology A/S (STO:SCOL)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.0041
-0.0027 (-39.71%)
Inactive · Last trade price on Jul 11, 2025
-39.71%
Market Cap962.53K
Revenue (ttm)n/a
Net Income (ttm)-56.32M
Shares Out234.76M
EPS (ttm)-0.25
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume29,309,360
Average Volume17,573,390
Open0.0067
Previous Close0.0068
Day's Range0.0037 - 0.0067
52-Week Range0.0037 - 0.9150
Beta1.79
RSI34.44
Earnings DateAug 28, 2025

About Scandion Oncology

Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company wa... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Employees 4
Stock Exchange Nasdaq Stockholm
Ticker Symbol SCOL
Full Company Profile

Financial Performance

Financial numbers in DKK Financial Statements

News

There is no news available yet.